Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
I invested money several years ago (during covid) and since then I have had an underlying feel/fear of "something not adding up". The tests suddenly don't materialise, then focus is pretty much fully switched to therapeutics with stunning inital results shared just a few months back.
How we get from there to this is actually beyond belief!
Complete lack of SH respect even though its stated otherwise.
Resign!
The below is from the Medusa 19 website......has this been updated to now say Avactas test as well? I also dont understand why Avacta themselves would not be speaking to Government departments directly if the tests are for professional use?
Medusa19
Shop |
MEDUSA 19
Testing for the Future
Join the thousands of people using science to return to work safely. Together we can pave the way back to normality.
As Trusted by
Our Testing Technology
Rapid Saliva Protein Test | Medusa19
Rapid Saliva Protein Test
The Rapid Saliva Protein Test (RSPT), from Medusa 19, provides results on the spot in 15 minutes. It is a lateral flow test (LFT) using a simple saliva sample to indicate the immune response to infection, particularly in patients who do not know they have an active SARS-CoV-2 infection and have no specific symptoms.
The RSPT is a simple, non-invasive, on the spot test indicating the immune response to infection from SARS-CoV-2, the virus underlying COVID-19. The LFT requires a simple saliva sample, a comfortable and non-invasive collection process, providing rapid results within 15 minutes.
Developed in the UK and Spain, the test indicates a user's immune response to SARS-CoV-2.
Relative sensitivity of 92%, relative specificity of 98% and 97% accuracy.
Avacta Antigen Test | Medusa19
Avacta Antigen Test
Medusa 19 has entered into a distribution agreement with Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, for its COVID-19 rapid antigen test that is currently under development.
This agreement provides Medusa 19 with exclusive distribution rights to consumers and non-exclusive distribution rights to businesses.
The test will indicate whether an individual has the COVID-19 infection and is intended to provide a result within minutes.
See more on the Avacta site or via our news section.
Affiliated to The National Microbiology Framework
We are proud to announce that Medusa 19 has been approved by the NHS Microbiology Framework Lot 1 for Goods and Services, for the supply of SARS-CoV-2 Lateral Flow Tests throughout the UK.
Medusa 19 are one of multiple selected suppliers to this Framework Contract which will run for the next 4 years and has a value of up to £3 Billion.
This Framework Contract allows the provision to all UK Government Departments and Trusts across England, Scotland, Northern Ireland and Wales subject to access agreement signature and Schedule 6 pricing, to supply the Rapid Saliva Protein Test (RSPT) and Avacta’s professional use AffiDx SARS-CoV-2 Antigen Lateral Flow Tests.
The Medusa tests detailed above and other parties lateral flow tests are now available for purchase by various government departments subject to their demand requirements.
Long time shareholder here....HOWEVER I must admit that I am starting to develop a sense of "being taken for a ride" with this share.Think I got caught up in the hype!Still think there is longer term potential here but I always feel the goal posts are constantly moved.
If this investor meeting is to coincide with the launch of the LFT then I find it strange why David Wilson would not be present, either alongside or instead of Neil Bell.
Anyhow, heres hoping we finally get to see what the last 12 months have brought to fruition.
Make it good ffs!
Who knows, just trying to connect the dots. To be fair credit goes to unprecendented for initially sharing the document a few months ago.
It could be completely unrelated of course but personally I feel by the end of the month we will have our answer.
Fingers crossed & GL all!
Hi Lolarch,
Yes if you assume the document (like many) refers to the rapid test consortium, and then scroll to page 5 you will see the 19th April date set as.....
"Start of significant standardised volumes" in terms of manufacuring.
Seem to tie in well with AVACTA just about to launch the LFT wouldnt you say.
DYOR of course.
If its not us then I think there will be many who will be 'perplexed', given the fact that there have been more clues given than that in a Columbo movie.
None more so than the switch to Anterior Nasal.
Lets wait and see as nothing is a given but I bloody hope it is us - just imagine SEEING the name Avacta in every UK household.